NCT02492620View on ClinicalTrials.gov

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Chronic Kidney DiseaseHyperphosphatemiaIron Deficiency AnemiaRenal Insufficiency
Interventions
DRUG

Ferric Citrate

Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis

Trial Locations (1)

80230

Denver Nephrologists, P.C., Denver

Sponsors

Collaborators (1)

Keryx Biopharmaceuticals
All Listed Sponsors
collaborator

Keryx Biopharmaceuticals

INDUSTRY

lead

Denver Nephrologists, P.C.

OTHER